Business Context and Reporting Period
This Form 8-K filing by Black Diamond Therapeutics, Inc. (BDTX) reports a material definitive agreement entered into on February 1, 2021. The company is a Delaware corporation with principal executive offices in Cambridge, MA, and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $150,000,000 in gross proceeds through an at-the-market offering.
Material Changes
- Entry into Sales Agreement: The Company entered into an Open Market Sale Agreement with Jefferies LLC.
- Capital Raising Capacity: The agreement permits the issuance and sale of common stock with an aggregate offering price of up to $150,000,000.
- Commission Structure: The Company agreed to pay Jefferies a cash commission of 3.0% of the gross proceeds from any shares sold.
Outlook, Risks, and Management Commentary
Offering Mechanics: Shares will be sold via an "at-the-market" offering as defined under Rule 415(a)(4). The Company has no obligation to sell any shares and may determine the timing and amounts of sales. Either party may suspend or terminate the offering upon notice.
Legal and Regulatory: The offering is subject to the Company's automatic shelf registration statement on Form S-3ASR. The filing explicitly states it does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful.
Contingencies: The offering will terminate upon the earlier of the sale of all authorized shares or the termination of the Sales Agreement.
Investor Verification Checklist
- Verify the current market price of BDTX common stock to assess the potential dilution impact of a $150 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Monitor subsequent filings for actual sales activity and the total amount of capital raised under this agreement.
- Confirm the Company's current cash position and burn rate to understand the urgency of this capital raise.